Type:Capsule
Generic Name:Oxytetracycline
Manufacturer:Doctor's Chemicals Works Ltd.
Price:৳0.00
Acne, Susceptible infections, Uncomplicated gonorrhoea
Should be taken on an empty stomach. Take on an empty stomach 1 hr before or 2 hr after meals.
Oral Susceptible infections Adult: 250-500 mg 4 times daily. Max 4 g daily. Acne Adult: 250-500 mg bid. Uncomplicated gonorrhoea Adult: 1.5 g initially, followed by 0.5 g four times daily up to a total of 9 g per treatment course. Intramuscular Susceptible infections Adult: 250 mg once daily or 300 mg daily in 2-3 divided doses.
Oral Susceptible infections Child: >8 yr: 25-50 mg/kg daily in 4 divided doses. Intramuscular Susceptible infections Child: >8 yr: 15-25 mg/kg (max 250 mg) daily in 2-3 divided doses.
Renal impairment: Dosage may need to be reduced.
Hypersensitivity to tetracyclines, children <8 yr, renal damage. Pregnancy, lactation.
Oxytetracycline binds reversibly to the 30S and possibly 50S ribosomal subunits, thus inhibiting bacterial protein synthesis and arresting cell growth. It is active against a wide range of gram-positive and gram-negative organisms.
Elderly, renal or hepatic impairment; myasthenia gravis; lupus erythematosus, children <12 yr.
Anorexia, nausea, vomiting,diarrhoea, glossitis, dysphagia, photosensitivity, oesphageal irritation and ulceration, nephrotoxicity, enterocolitis, rash (rare), blood dyscrasias. Headache, visual disturbances; intracranial hypertension; bulging fontanelles (infants). Potentially Fatal: Rare. Fulminant diarrhoea in post operative patients.
Antacids, iron, aluminum, calcium, magnesium, zinc salts reduce absorption. Concurrent use may cause increased levels of lithium, digoxin, halofantrine and theophylline; decreased concentrations of atovaquone. Increased risk of ergotism with ergot alkaloids. May cause failure of oral contraception. Potentially Fatal: Interferes with anticoagulant control. Nephrotoxic effects exacerbated by diuretics, methoxyflurane or other nephrotoxic drugs; avoid concurrent use with potentially hepatotoxic drugs. Increased incidence of benign intracranial hypertension with retinoids.
